We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Qiagen NV | NYSE:QGEN | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.0375 | -0.09% | 42.7725 | 42.82 | 42.30 | 42.70 | 831,853 | 20:01:47 |
HILDEN, Germany, GERMANTOWN, Maryland and BRIDGEWATER, New Jersey, August 21, 2017 /PRNewswire/ --
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced they have implemented the PAXgene® Blood ccfDNA Tube* sample collection in Clinical Genomics' Colvera™ colorectal cancer ("CRC") recurrence assay. Colvera, an integrated liquid biopsy solution, is designed to enable easy and accurate monitoring for recurrence of colorectal cancer with a simple blood test collected in a physician's office.
"The Colvera test represents a unique opportunity for convenient, non-invasive monitoring of colorectal cancer patients by detecting methylated circulating tumor DNA that may indicate recurrence of a cancer. We are pleased to collaborate with Clinical Genomics in expanding the range of benefits made possible through liquid biopsies, which hold great promise for improving the lives of patients in cancer and other fields of medicine," said Thierry Bernard, Senior Vice President and Head of QIAGEN's Molecular Diagnostics Business Area.
"We are extremely pleased to use the highly automated QIAsymphony PAXgene Blood ccfDNA collection and sample processing workflow for collection and handling of Colvera samples. As a long-term commercial and research partner of QIAGEN, we have a great deal of confidence in this new solution," said Dr. Lawrence LaPointe, CEO of Clinical Genomics. "We are excited to roll out the PAXgene System as the front-end solution to allow physicians to provide Colvera testing to CRC patients as conveniently as possible. PAXgene allows a simple blood collection at the physician's office, with no on-site processing required, which is a great step forward from our alternative sample collection methods."
Click here for the full press release
http://corporate.qiagen.com/newsroom/press-releases/2017/2017-08-21-PAXgene-Colvera
Contacts:
QIAGEN
Investor Relations
John Gilardi
+49-2103-291-1711
e-mail:ir@QIAGEN.com
Public Relations
Dr. Thomas Theuringer
+49-2103- 291-1826
e-mail: pr@QIAGEN.com
CLINICAL GENOMICS
Media
Patty Jenkins
+1-908-300-8673
e-mail:ir@clinicalgenomics.com
SOURCE QIAGEN N.V.
Copyright 2017 PR Newswire
1 Year Qiagen NV Chart |
1 Month Qiagen NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions